Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus
Authors: Parag Mahale, Jeffrey S. Glenn, Thomas R. O’Brien
Journal: Annals of Internal Medicine (2017)

Letters21 November 2017Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C VirusParag Mahale, MBBS, PhD, MPH, Jeffrey S. Glenn, MD, PhD, and Thomas R. O’Brien, MD, MPHParag Mahale, MBBS, PhD, MPHNational Cancer Institute, Rockville, Maryland (P.M., T.R.O.)Search for more papers by this author, Jeffrey S. Glenn, MD, PhDStanford University, Palo Alto, California (J.S.G.)Search for more papers by this author, and Thomas R. O’Brien, MD, MPHNational Cancer Institute, Rockville, Maryland (P.M., T.R.O.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0476 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read with interest Bersoff-Matcha and colleagues' article on 29 cases of hepatitis B virus (HBV) reactivation among persons co-infected with HBV/hepatitis C virus (HCV) who attained sustained virologic response after direct-acting antiviral (DAA) therapy for HCV infection (1). Among these patients, all but 1 of whom were reported to the U.S. Food and Drug Administration Adverse Event Reporting System, 2 died and 1 required liver transplantation. These important findings highlight viral interactions that can develop in persons who are chronically infected with multiple hepatitis viruses (2). Bersoff-Matcha and colleagues' article provides details on HBV infection variables ...References1. Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med. 2017;166:792-8. [PMID: 28437794]. doi:10.7326/M17-0377 LinkGoogle Scholar2. Lin L, Verslype C, van Pelt JF, van Ranst M, Fevery J. Viral interaction and clinical implications of coinfection of hepatitis C virus with other hepatitis viruses. Eur J Gastroenterol Hepatol. 2006;18:1311-9. [PMID: 17099381] CrossrefMedlineGoogle Scholar3. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73-85. [PMID: 21511329] doi:10.1016/S0140-6736(10)61931-9 CrossrefMedlineGoogle Scholar4. Kucirka LM, Farzadegan H, Feld JJ, Mehta SH, Winters M, Glenn JS, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis. 2010;202:845-52. [PMID: 20701536] doi:10.1086/655808 CrossrefMedlineGoogle Scholar5. Kushner T, Serper M, Kaplan DE. Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes. J Hepatol. 2015;63:586-92. [PMID: 25962883] doi:10.1016/j.jhep.2015.04.025 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: National Cancer Institute, Rockville, Maryland (P.M., T.R.O.)Stanford University, Palo Alto, California (J.S.G.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0476. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System Susan J. Bersoff-Matcha , Kelly Cao , Mihaela Jason , Adebola Ajao , S. Christopher Jones , Tamra Meyer , and Allen Brinker Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus Susan J. Bersoff-Matcha , Kelly Cao , Mihaela Jason , S. Christopher Jones , and Allen Brinker Metrics Cited byThe safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidenceHepatitis B virus and hepatitis C virus infection in immunocompromised patients 21 November 2017Volume 167, Issue 10Page: 759-760KeywordsAntiviral therapyDisclosureHepatitis AHepatitis B virusHepatitis DHepatitis D virusInfectious hepatitisLiver diseasesLiver transplantationTreatment guidelines ePublished: 21 November 2017 Issue Published: 21 November 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...